Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

Paclitaxel-Eluting Stents versus Everolimus-Eluting Coronary Stents in a Diabetic Population: 2 Years Follow-up of TUXEDO-India Trial.

Kaul U, Bhagwat A, Pinto B, Goel PK, Jagtap P, Sathe S, Wander GS, Arambam P, Bangalore S.

EuroIntervention. 2017 Jul 25. pii: EIJ-D-17-00333. doi: 10.4244/EIJ-D-17-00333. [Epub ahead of print]

2.

Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.

El-Mokadem M, El-Ramly M, Hassan A, Boshra H, AbdelWahab A.

Cardiovasc Revasc Med. 2017 May 31. pii: S1553-8389(17)30182-3. doi: 10.1016/j.carrev.2017.05.018. [Epub ahead of print]

PMID:
28625402
3.

Coronary Stents in Diabetic Patients: State of the Knowledge.

Codner P, Gurm HS, Motivala A.

Curr Cardiol Rep. 2017 Apr;19(4):28. doi: 10.1007/s11886-017-0837-y. Review.

PMID:
28315123
4.

New-Generation Coronary Stents: Current Data and Future Directions.

Kalra A, Rehman H, Khera S, Thyagarajan B, Bhatt DL, Kleiman NS, Yeh RW.

Curr Atheroscler Rep. 2017 Mar;19(3):14. doi: 10.1007/s11883-017-0654-1. Review.

PMID:
28220461
5.

A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.

Giannini F, Latib A, Ancona MB, Costopoulos C, Ruparelia N, Menozzi A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Colombo A.

Catheter Cardiovasc Interv. 2017 Jan 21. doi: 10.1002/ccd.26929. [Epub ahead of print]

PMID:
28109036
6.

Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.

Bavishi C, Baber U, Panwar S, Pirrotta S, Dangas GD, Moreno P, Tamis-Holland J, Kini AS, Sharma SK.

Int J Cardiol. 2017 Mar 1;230:310-318. doi: 10.1016/j.ijcard.2016.12.116. Epub 2016 Dec 27.

PMID:
28062139
7.

Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.

Rittger H, Wöhrle J, Brachmann J, Hohenforst-Schmidt W, Schlundt C, Lonke S, von Cranach M, Markovic S, Achenbach S, Waliszewski M.

Catheter Cardiovasc Interv. 2016 Oct;88(4):529-534. doi: 10.1002/ccd.26451. Epub 2016 Feb 19.

PMID:
26893095
8.

Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials.

Xhepa E, Tada T, Kufner S, Ndrepepa G, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Cassese S, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.

Catheter Cardiovasc Interv. 2017 Jan;89(1):1-10. doi: 10.1002/ccd.26645. Epub 2016 Aug 12.

PMID:
27515100
9.

Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study.

Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O.

Circ Cardiovasc Interv. 2016 Apr;9(4):e003316. doi: 10.1161/CIRCINTERVENTIONS.115.003316.

10.

Comparison of Angiographic and 1-Year Outcomes Between a Long Single Stent and Overlapping Double Stents in Patients With Newer-Generation Drug-Eluting Stents for Long Narrowings.

Mori N, Okamoto N, Tanaka A, Yano M, Makino N, Egami Y, Shutta R, Sakata Y, Tanouchi J, Nishino M.

Am J Cardiol. 2016 Jun 1;117(11):1724-8. doi: 10.1016/j.amjcard.2016.03.004. Epub 2016 Mar 18.

PMID:
27062939
11.
12.

Drug-Eluting Stents in Coronary Arteries [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2014 Dec 18.

13.

Comparison of Clinical and Angiographic Outcomes After Bare Metal Stents and Drug-Eluting Stents Following Rotational Atherectomy.

Tamura H, Miyauchi K, Dohi T, Tsuboi S, Ogita M, Kasai T, Okai I, Katoh Y, Miyazaki T, Naito R, Konishi H, Yokoyama K, Okazaki S, Isoda K, Kurata T, Daida H.

Int Heart J. 2016;57(2):150-7. doi: 10.1536/ihj.15-222. Epub 2016 Mar 11.

14.

Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.

Stella SF, Gehling Bertoldi E, Polanczyk CA.

Med Decis Making. 2016 Nov;36(8):1034-42. doi: 10.1177/0272989X16636054. Epub 2016 Mar 10.

PMID:
26964876
15.

Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.

Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.

Clin Res Cardiol. 2016 Jul;105(7):575-84. doi: 10.1007/s00392-015-0953-x. Epub 2015 Dec 22.

PMID:
26689707
16.

Relative dose and vascular response after drug-eluting stent implantation: A dosimetric 3D-intravascular ultrasound study.

Kitahara H, Waseda K, Yamada R, Sakamoto K, Yock PG, Fitzgerald PJ, Honda Y.

Int J Cardiol. 2016 Feb 1;204:211-7. doi: 10.1016/j.ijcard.2015.11.130. Epub 2015 Nov 30.

PMID:
26681540
17.

Stent failure due to simultaneous aggressive neoatherosclerosis of first- and current-generation drug-eluting stents.

Komukai K, Bernelli C, Sirbu V, Guagliumi G.

EuroIntervention. 2015 Nov;11(7):e1-2. doi: 10.4244/EIJV11I7A157. No abstract available.

18.

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.

Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, Banker D, Abhyankar A, Mullasari AS, Shah S, Jain R, Kumar PR, Bahuleyan CG; TUXEDO–India Investigators.

N Engl J Med. 2015 Oct 29;373(18):1709-19. doi: 10.1056/NEJMoa1510188. Epub 2015 Oct 14. Erratum in: N Engl J Med. 2016 Jul 28;375(4):398. Abhaychand, Rajpal K [Corrected to Abhaichand, Rajpal K].

19.

Two-year clinical outcome in patients with small coronary artery disease treated with everolimus- versus paclitaxel-eluting stenting.

Nasu K, Oikawa Y, Shirai S, Hozawa H, Kashima Y, Tohara S, Kadotani M, Gotoh R, Ujiie Y, Tanabe M, Abe H, Okamura A, Tsuji T, Suzuki M, Takeda Y, Mibiki Y, Ota H, Usui S, Nakagawa Y, Kawaguchi R, Yamashita J, Serikawa T, Aizawa T, Suzuki T; SACRA and PLUM registries investigators.

J Cardiol. 2016 Sep;68(3):209-14. doi: 10.1016/j.jjcc.2015.08.024. Epub 2015 Oct 9.

PMID:
26454428
20.

Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study.

Worthley S, Hendriks R, Worthley M, Whelan A, Walters DL, Whitbourn R, Meredith I.

Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):413-7. doi: 10.1016/j.carrev.2015.07.009. Epub 2015 Aug 10.

Supplemental Content

Loading ...
Support Center